Ambu downgrades, will cut costs
The Danish medtech firm’s preliminary Q3 report for 2021/2022 announced a cost reduction program, which will affect staffing and is expected to yield DKK 250m (USD 34.1m) in annualized savings.
by manon skov buch, translated by daniel pedersen
On Wednesday, Danish medtech firm Ambu announced preliminary financial figures from the third quarter of fiscal 2021/2022 – alongside a guidance downgrade for the full-year and a cost reduction program meant to result in DKK 250m (USD 34.1m) annualized savings.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA clears Ambu's new bronchoscope generation
For subscribers
Britt Meelby Jensen wants to rebuild trust in Ambu
For subscribers
